HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by FitzGerald, J M Articles by Gibson, P G Search for Related Content PubMed PubMed Citation Articles by FitzGerald, J M Articles by Gibson, P G

Asthma exacerbations · 4: Prevention

¹ Centre for Clinical Epidemiology and Evaluation, University of British Columbia, Vancouver, Canada
² Department of Respiratory and Sleep Medicine, John Hunter Hospital, Hunter Medical Research Institute, Newcastle, Australia

Correspondence to:
Correspondence to:
Professor J M FitzGerald
Centre for Clinical Epidemiology and Evaluation, Vancouver Coastal Research Institute, Vancouver General Hospital, Vancouver, BC, V5Z 1L8, Canada; markf @interchange.ubc.ca

Asthma exacerbations are common. They account for a significant morbidity and contribute a disproportionate amount to the cost of asthma management. The optimal strategies for the prevention of asthma exacerbations include the early introduction of anti-inflammatory treatment—most commonly, low dose inhaled corticosteroids. This should be coupled with a structured education programme which has a written action plan as an integral component. Where patients continue to be poorly controlled, the addition of a long acting ß agonist should be considered. The latter should not be used as monotherapy and should always be used with inhaled corticosteroids. Atopic patients with a history of repeated exacerbations, especially if they are steroid dependent and with a raised IgE, may be considered as potential candidates for omalizumab. In the early stages of an asthma exacerbation, doubling the dose of inhaled corticosteroids has been shown to be ineffective. The ideal strategy for the management of worsening asthma in patients on combination treatment, especially salmeterol and fluticasone, is uncertain. There is an emerging body of evidence for strategies on how to prevent progression to an exacerbation in patients taking a combination of budesonide and formoterol.

Abbreviations: FEV₁, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; LABA, long acting ß agonist; LTRA, leukotriene receptor antagonist; OCS, oral corticosteroid; PEF, peak expiratory flow

Keywords: asthma; exacerbation; prevention; education; management

This article has been cited by other articles:

				A B Chang and D Bilton Exacerbations in cystic fibrosis: 4 {middle dot} Non-cystic fibrosis bronchiectasis Thorax, March 1, 2008; 63(3): 269 - 276. [Abstract] [Full Text] [PDF]

				L.-P. Boulet Review: inhaled corticosteroids reduce hospital admission and increase discharge rate during the first 4 hours in the emergency department for acute asthma Evid. Based Med., June 1, 2007; 12(3): 75 - 75. [Full Text] [PDF]